Chiou-Hong Lin

Chiou-Hong Lin has a strong background in scientific research, particularly in the fields of oncology, hematology, and pathology. They started their career as a Research Assistant at National Taiwan University, working on yeast genetics and cell biology. They then moved on to a position as a Postdoctoral Fellow at Academia Sinica, where they focused on protein modifications and their role in cancer pathogenesis. They continued their research as a Postdoctoral Fellow at Stanford University School of Medicine, investigating the pathogenesis mechanisms of acute leukemia and cardiac hypertrophy. During this time, they published multiple papers related to their research. After their postdoctoral work, they joined AbbVie as a Senior Scientist, where they worked on small molecule drug treatments in acute leukemia. Currently, they hold the position of Principal Scientist at Scorpion Therapeutics.

Chiou-Hong Lin earned a Bachelor of Science degree in Agricultural Chemistry from National Taiwan University in 1999. From 1999 to 2001, they pursued a Master of Science degree in Biochemistry from the Institute of Agricultural Chemistry at National Taiwan University. Chiou-Hong then went on to complete a Doctor of Philosophy degree in Biomedical Sciences and Cancer Biology at National Defense University from 2002 to 2010.